Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Short-term Investments (2018 - 2026)

Ovid Therapeutics filings provide 8 years of Short-term Investments readings, the most recent being $61.5 million for Q1 2026.

  • Quarterly Short-term Investments rose 181.14% to $61.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $61.5 million through Mar 2026, up 181.14% year-over-year, with the annual reading at $56.5 million for FY2025, 110.96% up from the prior year.
  • Short-term Investments hit $61.5 million in Q1 2026 for Ovid Therapeutics, up from $56.5 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $84.1 million in Q4 2022 and bottomed at $5.0 million in Q3 2025.
  • Average Short-term Investments over 5 years is $48.0 million, with a median of $51.2 million recorded in 2023.
  • The largest annual shift saw Short-term Investments plummeted 89.53% in 2025 before it skyrocketed 181.14% in 2026.
  • Ovid Therapeutics' Short-term Investments stood at $84.1 million in 2022, then decreased by 6.35% to $78.8 million in 2023, then crashed by 66.02% to $26.8 million in 2024, then skyrocketed by 110.96% to $56.5 million in 2025, then rose by 8.81% to $61.5 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Short-term Investments are $61.5 million (Q1 2026), $56.5 million (Q4 2025), and $5.0 million (Q3 2025).